[SCHEDULE 13G] Vir Biotechnology, Inc. Passive Investment Disclosure (>5%)
Rhea-AI Filing Summary
Vir Biotechnology Inc ownership filing: Vanguard Portfolio Management reports beneficial ownership of 9,257,235 shares of Vir Biotechnology common stock, representing 5.79% of the class. The filing shows sole dispositive power over 9,257,235 shares and sole voting power for 41,658 shares. Vanguard states these holdings reflect positions managed by Vanguard Portfolio Management LLC and affiliated business divisions, including securities held by Vanguard funds and certain client accounts. The filing is signed by a Vanguard official.
Positive
- None.
Negative
- None.
Insights
Large passive stake reported by Vanguard, typical Schedule 13G disclosure.
Vanguard Portfolio Management reports beneficial ownership of 9,257,235 shares, equal to 5.79% of Vir Biotechnology’s common stock. The filing lists dispositive and limited voting power consistent with index/managed-fund holdings.
Such 13G filings typically indicate passive, investment-company holdings rather than activist intent; subsequent changes would appear in amended filings if Vanguard’s role or percentage shifts.